Bartlett John M S, Campbell Fiona M, Mallon Elizabeth A
Endocrine Cancer Group, Edinburgh University Cancer Research Centre, Western General Hospital, Edinburgh, Scotland, UK.
Am J Clin Pathol. 2008 Dec;130(6):920-6. doi: 10.1309/AJCPSDG53BEANCYE.
Our purpose was to determine the accuracy of diagnosis of HER2 amplification by analysis of HER2 copy number. HER2 and chromosome 17 were measured by dual-color fluorescence in situ hybridization in breast cancer samples. At a HER2 copy number of 2 to less than 3, 16 (3.3%) of 488 cases had HER2 amplification; and at a copy number of 3 to less than 4, 32 (16.4%) of 195 cases were amplified. The proportion of cases with HER2 amplification increased considerably at HER2 copy numbers of 4 to less than 7: 50.0% at 4 to less than 5; 67.5% at 5 to less than 6, and 77.3% at 6 to less than 7. Virtually all cases were amplified at HER2 copy numbers of 7 or more. We recommend that all breast cancer cases with a HER2 copy number of 2 to 7 determined by single-color in situ hybridization should also be analyzed for chromosome 17 to obtain a more accurate diagnosis of HER2 amplification.
我们的目的是通过分析HER2拷贝数来确定HER2扩增诊断的准确性。采用双色荧光原位杂交技术检测乳腺癌样本中的HER2和17号染色体。在HER2拷贝数为2至小于3时，488例中有16例（3.3%）出现HER2扩增；在拷贝数为3至小于4时，195例中有32例（16.4%）出现扩增。在HER2拷贝数为4至小于7时，HER2扩增病例的比例大幅增加：4至小于5时为50.0%；5至小于6时为67.5%，6至小于7时为77.3%。实际上，所有HER2拷贝数为7或更高的病例均出现扩增。我们建议，对于通过单色原位杂交确定HER2拷贝数为2至7的所有乳腺癌病例，也应分析17号染色体，以获得更准确的HER2扩增诊断。
